ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study

  • 期刊论文

  • 发表日期：

    2024年5月14日

查看全文
  • Matilde Corianò,
  • Chiara Tommasi,
  • Anh Thi Lan Dinh,
  • Jazmine Needham,
  • Hala Aziz,
  • Nalinie Joharatnam-Hogan,
  • Niamh Cunningham,
  • Jasmin Waterhouse,
  • Mingze Sun,
  • Fiona Turkes,
  • Benedetta Pellegrino,
  • Sophie McGrath,
  • Alicia Okines,
  • Marina Parton,
  • Nicholas Turner,
  • Stephen Johnston,
  • Antonino Musolino,
  • Alistair Ring,
  • Nicolò Matteo Luca Battisti

摘要

Purpose

Many patients with early breast cancer (eBC) undergoing neoadjuvant chemotherapy do not achieve pathological complete response (pCR), which is a prognostic factor. We examined the role of HER2-low expression in predicting pCR and prognosis in HER2-negative eBC.

Methods

We evaluated patients with stage I-III HER2-negative BC, treated between 2013 and 2023 at The Royal Marsden NHS Foundation Trust, London. Tumors were classified based on estrogen receptor (ER) status and into HER2-low and HER2-zero subgroups. We analyzed pCR rates, relapse-free survival (RFS) and overall survival (OS).

Results

754 patients were included in the analysis. pCR rate was 8.9% in the ER+ /HER2-low, 16.5% in the ER+ /HER2-zero, 38.9% in the ER- ER-/HER2-low and 35.9% in the ER-/HER2-zero eBC (p < 0.001). Multivariable analysis showed a significantly lower pCR rate in HER2-low compared to HER2-zero BC in the ER+ subgroup. At a median follow-up of 63.8 months (59.9–67.4), we observed longer OS in HER2-low compared to HER2-zero patients in the overall and in the ER+ population. There was no predictive or prognostic impact of HER2-low status in the ER- population.

Conclusion

This study supports the interpretation of HER2 status as a possible prognostic and predictive biomarker for HER2-negative eBC, especially among patients with ER+ disease.